anorexia nervosa
Conditions
Interventions
Functional connectivity of brain regions by rs-fMRI/ Patient treated with MANTRA
Functional connectivity of brain regions by rs-fMRI / Normal controls
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patient treated with MANTRA 1.Diagnosed as AN by DSM-5 2.BMI 15 or more and less than 18.5 3.Women between the ages of 18 to 55 4.Patients who obtained consent from this study by signing consent form with their own or his / her consent Normal controls 1.BMI 18 or more and less than 25 2. Women between the ages of 18 to 55 3.Subjects who obtained consent from this study by signing consent form with their own or his / her consent
Exclusion criteria
Exclusion criteria: Patient treated with MANTRA 1.When the main psychiatric disorders is other than AN 2.Patient with severe physical complications 3.Pregnant 4.Serious suicidal ideation or suicide-related behavior is observed 5.Inappropriate patients for this study judged by physician Normal controls 1.If the subjects has a history of psychiatric / neurological disorders, including eating disorders, within themselves and within their first degree
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| resting-state functional MRI | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Body Mass Index(BMI) 2.Eating Disorder Instrument-2(EDI-2) 3.Bulimic Investigatory Test, Edinburgh (BITE) 4.Beck Depression Inventory-2 (BDI-2) 5.State-Trait Anxiety Inventory (STAI) 6.Obsessive Compulsive Inventory(OCI) 7.Liebowitz Social Anxiety Scale(LSAS) 8.Work and Social Adjustment Scale(WSAS) 9.Visual Analogue Scale(VAS): Evaluate treatment motivation, credibility, acceptability, and social support on a scale of 0-10.(only patient treated with MANTRA) 10.Metabolite concentration in the brain measured by H-MRS with measurement area set in medial prefrontal cortex and analyzed by LCModel. 11.Cytokine, Chemokine, growth factor: eotaxin, FGF-2, G-CSF, GM-CSF, IFN-g, IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IP-10, MCP-1(MCAF), MIP-1a, MIP-1b, PDHF-BB, RANTES, TNF-a, VEGF, CTACK, GRO-a, HGF, ICAM-1, IFN-a2, IL-1a, IL-2Ra, IL-3, IL-12p40, IL-16, IL-18, LIF, MCP-3, M-CSF, MIF, MIG, b-NGF, SCF, SCGF-b, SDF-1a, TNF-b, TRAIL, VCAM-1 12.T1 weighted image 13.T2 weighted image | — |
Countries
Japan
Contacts
Public ContactTomoyo Isobe
Hamamatsu University Hospital Department of Psychiatry
Outcome results
None listed